Comprehensive medication guide to Gemtesa including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$30/month for commercially insured patients with coverage using the Simple Savings Program; $100–$200/month for Medicare Part D patients (Tier 4); prior authorization commonly required.
Estimated Cash Pricing
$612–$692 retail for brand-name Gemtesa (no generic available); as low as $470 with GoodRx Gold or $442 with SingleCare coupons for a 30-day supply.
Medfinder Findability Score
78/100
Summarize with AI
On this page
Gemtesa is a brand-name prescription medication containing the active ingredient vibegron. It is a once-daily 75 mg tablet used to treat overactive bladder (OAB) in adults. Manufactured by Sumitomo Pharma America, Gemtesa was first FDA-approved in December 2020 and commercially launched in the United States in April 2021.
Gemtesa has two FDA-approved indications: (1) OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults, and (2) OAB in adult males who are on pharmacological therapy for benign prostatic hyperplasia (BPH) — the second indication approved in December 2024.
There is no generic version of Gemtesa available as of 2026. Patent protection is expected to prevent generic entry until the early 2030s. Gemtesa is available only as a brand-name product and must be obtained with a valid prescription from a licensed healthcare provider.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Gemtesa (vibegron) is a selective beta-3 adrenergic receptor agonist. It works by binding to beta-3 adrenergic receptors (β3-ARs) located on the detrusor smooth muscle in the bladder wall. When these receptors are activated, a molecular signaling cascade is triggered: adenylate cyclase is activated, which increases intracellular cyclic AMP (cAMP), which activates protein kinase A and reduces intracellular calcium levels.
The net result is relaxation of the detrusor smooth muscle during bladder filling. A more relaxed bladder has greater capacity — meaning it can hold more urine before triggering the urgent need to void. This directly addresses the urgency, frequency, and incontinence episodes characteristic of OAB.
A key advantage of this mechanism: Gemtesa does not inhibit CYP2D6 or other cytochrome P450 enzymes, and it does not cross the blood-brain barrier. This results in fewer drug interactions than mirabegron and no cognitive side effects — unlike anticholinergic OAB drugs. Steady-state plasma concentrations are reached within 7 days of once-daily dosing.
75 mg — tablet
Once-daily film-coated oval light green tablet; can be swallowed whole or crushed and mixed with applesauce; take with or without food
Gemtesa is not listed on the FDA drug shortage database as of 2026. Its national supply chain is stable. However, patients frequently report difficulty filling their prescriptions due to several real-world barriers: not all pharmacies stock it regularly, insurance prior authorization is commonly required, and the retail cash price of $612–$692/month is prohibitive without financial assistance.
If you're having trouble filling your Gemtesa prescription, medfinder can call pharmacies near you on your behalf to find which ones have it in stock and text you the results. Larger chain pharmacies (CVS, Walgreens) and mail-order services (CVS Caremark, Express Scripts) typically carry Gemtesa more reliably than smaller independent pharmacies.
The Gemtesa Simple Savings Program can significantly reduce cost barriers: commercially insured patients with coverage can pay as little as $10/month, and those without coverage can pay $95/month. Uninsured patients may qualify for the patient assistance program. Once insurance and cost are sorted, most patients can fill Gemtesa reliably through larger retail or mail-order pharmacies.
Gemtesa (vibegron) is not a controlled substance and has no DEA schedule restrictions. Any licensed prescriber with authority to write prescriptions can prescribe it. No special certification, registration, or REMS requirement applies. Prescribers who commonly prescribe Gemtesa include:
Urologists — the most common specialist for OAB management
Urogynecologists — specializing in female pelvic floor disorders and OAB
OB/GYNs — frequently prescribe for women's OAB symptoms
Primary care physicians (PCPs) — family medicine and internal medicine doctors
Nurse practitioners (NPs) and physician assistants (PAs) — in urology, women's health, or primary care practices
Geriatricians — given Gemtesa's favorable cognitive safety profile in older adults
Gemtesa can also be prescribed via telehealth in most states. Because it is not a controlled substance, providers on virtual care platforms can evaluate OAB symptoms and prescribe Gemtesa during an online visit, sending the prescription electronically to your preferred pharmacy.
No. Gemtesa (vibegron) is not a controlled substance under the DEA's Controlled Substances Act. It has no DEA schedule. This means it can be prescribed by any licensed healthcare provider, called in or electronically prescribed without special restrictions, and prescribed via telehealth visits in most states.
There are no special registration requirements, REMS programs, or mandatory monitoring lab work required to prescribe Gemtesa. Refills follow standard prescription rules — your doctor can prescribe multiple refills on a single prescription. There are no early refill restrictions or mandatory monitoring associated with its non-controlled status.
Gemtesa is generally well-tolerated. The most common side effects reported in clinical trials (occurring in ≥2% of patients at a rate greater than placebo):
Headache
Urinary tract infection (UTI)
Nasopharyngitis (nasal congestion, runny nose, sore throat)
Diarrhea
Nausea
Upper respiratory tract infection
Serious side effects (rare but requiring medical attention):
Urinary retention — difficulty emptying the bladder; higher risk with bladder outlet obstruction or concurrent anticholinergic OAB medications
Angioedema — rare life-threatening swelling of face/throat; can occur after first dose or later; requires immediate emergency care
Know what you need? Skip the search.
Mirabegron ER (generic Myrbetriq)
Same beta-3 agonist mechanism; generic available since 2024 at lower cost; may raise blood pressure; inhibits CYP2D6
Oxybutynin (generic Ditropan XL)
Affordable anticholinergic; multiple forms (tablet, patch, gel); higher risk of dry mouth, constipation, and cognitive effects in elderly
Solifenacin (generic VESIcare)
Once-daily antimuscarinic with generic available; moderate anticholinergic side effects; also available as liquid suspension
Tolterodine (generic Detrol)
Affordable antimuscarinic with generic available in IR and ER forms; milder anticholinergic side effect profile than oxybutynin
Prefer Gemtesa? We can find it.
Digoxin
moderateVibegron increases digoxin Cmax by ~21% and AUC by ~11% via unknown mechanism (possibly P-gp). Monitor serum digoxin levels before and during treatment. Titrate digoxin dose as needed.
Anticholinergic OAB medications (oxybutynin, solifenacin, tolterodine, darifenacin)
moderateCombination increases risk of urinary retention. Use with caution under close medical supervision if combination is clinically necessary.
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir)
minorMay increase vibegron blood levels since vibegron is a CYP3A4 substrate. Clinical significance is not established at standard doses.
Gemtesa (vibegron) is a well-tolerated, once-daily treatment for overactive bladder that represents a meaningful advance over older anticholinergic medications. Its selective beta-3 mechanism avoids the dry mouth, constipation, blurred vision, and — critically — cognitive effects that have historically limited OAB pharmacotherapy, especially in older adults. For patients on complex medication regimens, its minimal drug interaction profile (no CYP2D6 inhibition) is a major clinical advantage.
The main challenges with Gemtesa in 2026 are cost and access. As a brand-only medication with a retail price of $612–$692/month, navigating insurance coverage and prior authorization is essential. The Gemtesa Simple Savings Program can dramatically reduce out-of-pocket costs for commercially insured patients. Uninsured patients may qualify for the patient assistance program at no cost.
If you have a prescription and are struggling to find a pharmacy with Gemtesa in stock, medfinder can call pharmacies near you and text back which ones can fill your prescription — saving you hours of phone calls.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini